Summary: A new study reveals the combination of ketamine with naltrexone can help treat symptoms of both depression and addiction.
The combination of naltrexone and ketamine can help treat both symptoms of addiction and depression, a preliminary study by Yale University researchers suggests.
Substance abuse and depression are common in many patients, and efforts to treat both conditions simultaneously have had limited success. One recent study suggested that the antidepressant effects of ketamine might blunted by administration of naltrexone, used to limit cravings of those addicted to opioid drugs and alcohol.
A preliminary study of five patients suffering from both depression and substance abuse disorders suggest that isn’t the case. The study was published Jan. 9 in the journal JAMA Psychiatry.
The results “raise the possibility that for people who have depression complicated by substance abuse disorders, the combination of ketamine and naltrexone may be a strategy to explore in the effort to optimally treat both conditions,” said senior author John Krystal, Yale’s Robert L. McNeil Jr. Professor of Translational Research; professor of psychiatry, neuroscience, and psychology; and chair of the Department of Psychiatry.
Krystal and lead author Gihyun Yoon, assistant professor of psychiatry, treated the five patients suffering from depression and alcohol use disorder with a long-lasting form of naltrexone and then administered ketamine. Four of the five responded to the first ketamine dose and all five found relief from depression after multiple doses.
The study also challenges the idea that ketamine might produce antidepressant effects by stimulating opiate receptors.
Krystal cautioned that larger studies are needed to confirm beneficial effects of the combination treatment.
Krystal and Yoon have provisional patents on the use of ketamine and naltrexone to treat comorbid depression and substance abuse.
[divider]About this neuroscience research article[/divider]
Funding: The study was primarily funded by the U.S. Department of Veterans Affairs.
Source: Bill Hathaway – Yale Publisher: Organized by NeuroscienceNews.com. Image Source: NeuroscienceNews.com image is in the public domain. Original Research: Abstract for “Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder” by Gihyun Yoon, MD; Ismene L. Petrakis, MD; and John H. Krystal, MD in JAMA Psychiatry. Published January 9 2019. doi:10.1001/jamapsychiatry.2018.3990
[divider]Cite This NeuroscienceNews.com Article[/divider]
[cbtabs][cbtab title=”MLA”]Yale “Ketamine and Naltrexone Combo Shows Promise for Depression and Addiction Treatments.” NeuroscienceNews. NeuroscienceNews, 10 January 2019. <http://neurosciencenews.com/depression-addiction-drug-combo-10489/>.[/cbtab][cbtab title=”APA”]Yale(2019, January 10). Ketamine and Naltrexone Combo Shows Promise for Depression and Addiction Treatments. NeuroscienceNews. Retrieved January 10, 2019 from http://neurosciencenews.com/depression-addiction-drug-combo-10489/[/cbtab][cbtab title=”Chicago”]Yale “Ketamine and Naltrexone Combo Shows Promise for Depression and Addiction Treatments.” http://neurosciencenews.com/depression-addiction-drug-combo-10489/ (accessed January 10, 2019).[/cbtab][/cbtabs]
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder
Ketamine has rapid and robust antidepressant effects. However, there are concerns about the abuse liability of ketamine.1 This concern was heightened recently owing to a preliminary report suggesting that antidepressant effects of ketamine might be dependent on opiate receptor stimulation.2 Below, we present pilot data that indicate that the antidepressant effects of ketamine are not attenuated by naltrexone pretreatment. As a result, the combination of opiate receptor antagonism with ketamine might be a strategy to reduce addiction risk among patients with depression at risk for substance abuse.
[divider]Feel free to share this Neuroscience News.[/divider]